Sean Hennessy, PharmD, PhD

faculty photo
Professor of Epidemiology in Biostatistics and Epidemiology
Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania
Fellow, Institute on Aging, University of Pennsylvania
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine
Founding Director, Center for Pharmacoepidemiology Research and Training (CPeRT), University of Pennsylvania Perelman School of Medicine
Investigator, Center for Pharmacoepidemiology Research and Training (CPeRT), University of Pennsylvania Perelman School of Medicine
Member, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine
Department: Biostatistics and Epidemiology
Graduate Group Affiliations

Contact information
University of Pennsylvania
423 Guardian Drive
803 Blockley Hall
Philadelphia, PA 19104-6021
Office: 215-898-9112
Fax: 215-573-5315
Education:
BS (Pharmacy)
Philadelphia College of Pharmacy and Science, 1989.
PharmD (Clinical Pharmacy)
Philadelphia College of Pharmacy and Science, 1990.
MSCE (Clinical Epidemiology)
University of Pennsylvania School of Medicine, 1996.
PhD (Epidemiology with Biostatistics minor)
University of Pennsylvania, 2002.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Sean Hennessy leads Penn's Center for Pharmacoepidemiology Research and Training (CPeRT), and conducts research in the field of pharmacoepidemiology, which is the study of the health effects of drugs and other medical products in populations. He and his colleagues identified a survival benefit of potassium supplementation in users of loop diuretics, and found that this survival benefit increases with hotter outdoor temperature. They also found that the survival benefits of statin drugs increases with hotter outdoor temperature. He and his colleagues study serious health consequences of drug-drug interactions involving high-risk drugs including anticoagulants, antidiabetes drugs, and antiplatelet agents. Their research has produced actionable knowledge about the cardiovascular safety of many widely-used drugs for mental health conditions in including ADHD, depression, and schizophrenia. They also evaluated an early approach to using health insurance data to improve prescribing, finding it ineffective despite its federal mandate. This contributed to the omission of a requirement for drug utilization review programs in Medicare Part D. He co-led a pair of studies that demonstrated the effectiveness and safety of the SA14-14-2 vaccine for Japanese encephalitis (JE), which subsequently led to the immunization of millions of children per year in populous countries including Cambodia, India, Malaysia, Nepal, Sri Lanka, and Thailand. Use of that vaccine has been credited with reducing the worldwide incidence of JE. He and his colleagues developed the trend-in-trend research design for studying the effects of rapidly increasing or declining exposures. He was the senior author of one of two citizen petitions to the US Food and Drug Administration that led to re-labeling of metformin, the best-proven therapy for type 2 diabetes, to permit its use in persons with mild to moderate renal insufficiency. He has served as chair of NIH's Health Services and Organizational Delivery study section and Health Services Quality and Effectiveness study section.

Description of Other Expertise

Dr. Hennessy has served as scientific program chair and president of the International Society for Pharmacoepidemiology, regional editor for the Americas of the journal Pharmacoepidemiology and Drug Safety, as a member of FDA’s Drug Safety and Risk Management Advisory Committee, and on the board of directors of the American Society for Clinical Pharmacology and Therapeutics. He is a co-editor of the books Pharmacoepidemiology, 6th edition and Textbook of Pharmacoepidemiology, 2nd edition.

Additional Positions:
Director, Center for Pharmacoepidemiology Research & Training
Interim Director, Division of Epidemiology, Department of Biostatistics, Epidemiology and Informatics
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
Senior Fellow, Leonard Davis Institute of Health Economics
Fellow, Institute on Aging
Member, Pharmacy and Therapeutics Committee, University of Pennsylvania Health System
Special Government Employee, US FDA
Member, Council for International Organizations of Medical Sciences (CIOMS) Work Group XIII on Real-World Data & Evidence in Regulatory Decision Making

Courses Led:
EPI 666: Pharmacoepidemiology Research Methods

Honors:
1998 Stanley A. Edlavitch Award for Best Abstract Submitted by a Student, International Society for Pharmacoepidemiology
2002 Saul Winegrad Award for Outstanding Dissertation in Epidemiology and Biostatistics, University of Pennsylvania
2005 Young Alumnus Award, University of the Sciences in Philadelphia
2008 Leon I Goldberg Young Investigator Award, American Society for Clinical Pharmacology & Therapeutics
2013 Samuel Martin Health Evaluation Sciences Research Award, University of Pennsylvania Perelman School of Medicine
2014 Julius W. Sturmer Memorial Lecture Award, Alpha Tau Chapter of the Rho Chi Society, Philadelphia College of Pharmacy, University of the Sciences
2015 Elected Member, National Academy of Medicine

Selected Publications

Flannery D, Passarella M, Mukhopadhyay S, Dhudasia M, Gerber J, Lorch S, Hennessy S, Puopolo K: Early childhood antibiotic utilization for infants discharged from the neonatal intensive care unit. Journal of Perinatology 2022 (https://doi.org/10.1038/s41372-022-01380-y).

Shah M, Hubbard RA, Mamtani R, Marmarelis ME, Hennessy S: Very high PD-L1 Expression as a prognostic indicator of overall survival among Patients with advanced non-small cell lung cancer receiving anti PD-(L)1 monotherapies in routine practice. Pharmacoepidemiology and Drug Safety 2022 (https://doi.org/10.1002/pds.5487).

Dhopeshwarkar N, Yang W, Hennessy S, Rhodes JM, Cuker A, Leonard CE: Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study. American Journal of Hematology 2022 (https://doi.org/10.1002/ajh.26632).

Chen C, Hennessy S, Brensinger CM, Dawwas GK, Acton EK, Bilker WB, Chung S, Dublin S, Horn JR, Miano TA, Pham Nguyen TP, Leonard CE: Skeletal muscle relaxant drug-drug-drug interactions and unintentional traumatic injury: Screening to detect three-way drug interaction signals. British Journal of Clinical Pharmacology 2022 (http://doi.org/10.1111/bcp.15395).

Dawwas GK, Hennessy S, Brensinger CM, Acton EK, Bilker WB, Chung S, Dublin S, Horn JR, Manis MM, Miano TA, Oslin DW, Pham Nguyen TP, Soprano SE, Wiebe DJ, Leonard CE: Signals of muscle relaxant drug interactions associated with unintentional traumatic injury: A population-based screening study. CNS Drugs 2022 (forthcoming).

Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson B, Wilson FP, Townsend R, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS: Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill Adults: a prospective cohort study. Intensive Care Medicine 2022 (forthcoming).

Dawwas DK, Flory JH, Hennessy S, Leonard CE, Lewis JD: Comparative safety of sodium glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis. Diabetes Care 2022 (doi: 10.2337/dc21-2177).

Ellis DE, Hubbard RE, Willis AR, Zuppa A, Zaoutis TE, Hennessy S: Comparative risk of serious hypoglycemia among persons dispensed a fluoroquinolone versus a non-fluoroquinolone antibiotic. Diabetes Research and Clinical Practice 2022 (doi: 10.1016/j.diabres.2022.109225).

Pham Nguyen TP, Soprano SE, Hennessy S, Brensinger CM, Bilker WB, Miano TA, Acton EK, Horn JR, Chung S, Dublin S, Oslin DW, Wiebe DJ, Leonard CE: Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury. Journal of Psychiatric Research 151: 299-303, 2022

George MD, Hsu JY, Hennessy S, Chen L, Xie F, Curtis JR, Baker JF: Risk of serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: an instrumental variable analysis. Epidemiology 33: 65-74, 2022.

back to top
Last updated: 06/28/2022
The Trustees of the University of Pennsylvania